Literature DB >> 22924785

Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L.

Justin L Anglin1, Lisheng Deng, Yuan Yao, Guobin Cai, Zhen Liu, Hong Jiang, Gang Cheng, Pinhong Chen, Shuo Dong, Yongcheng Song.   

Abstract

Histone3-lysine79 (H3K79) methyltransferase DOT1L has been found to be a drug target for acute leukemia with MLL (mixed lineage leukemia) gene translocations. A total of 55 adenosine-containing compounds were designed and synthesized, among which several potent DOT1L inhibitors were identified with K(i) values as low as 0.5 nM. These compounds also show high selectivity (>4500-fold) over three other histone methyltransferases. Structure-activity relationships (SAR) of these compounds for their inhibitory activities against DOT1L are discussed. Potent DOT1L inhibitors exhibit selective activity against the proliferation of MLL-translocated leukemia cell lines MV4;11 and THP1 with EC(50) values of 4-11 μM. Isothermal titration calorimetry studies showed that two representative inhibitors bind with a high affinity to the DOT1L:nucleosome complex and only compete with the enzyme cofactor SAM (S-adenosyl-L-methionine) but not the substrate nucleosome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22924785      PMCID: PMC3475323          DOI: 10.1021/jm300917h

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  29 in total

1.  Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase.

Authors:  Stefan Kubicek; Roderick J O'Sullivan; E Michael August; Eugene R Hickey; Qiang Zhang; Miguel L Teodoro; Stephen Rea; Karl Mechtler; Jennifer A Kowalski; Carol Ann Homon; Terence A Kelly; Thomas Jenuwein
Journal:  Mol Cell       Date:  2007-02-09       Impact factor: 17.970

2.  Thermodynamic Investigation of Inhibitor Binding to 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase.

Authors:  Guobin Cai; Lisheng Deng; Bartlomiej G Fryszczyn; Nicholas G Brown; Zhen Liu; Hong Jiang; Timothy Palzkill; Yongcheng Song
Journal:  ACS Med Chem Lett       Date:  2012-05-07       Impact factor: 4.345

Review 3.  Structural and sequence motifs of protein (histone) methylation enzymes.

Authors:  Xiaodong Cheng; Robert E Collins; Xing Zhang
Journal:  Annu Rev Biophys Biomol Struct       Date:  2005

4.  Pharmacokinetics of the antiviral agent 3-deazaneplanocin A.

Authors:  R A Coulombe; R P Sharma; J W Huggins
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Jul-Sep       Impact factor: 2.441

5.  Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9.

Authors:  Dorothea Greiner; Tiziana Bonaldi; Ragnhild Eskeland; Ernst Roemer; Axel Imhof
Journal:  Nat Chem Biol       Date:  2005-07-17       Impact factor: 15.040

Review 6.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

7.  Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain.

Authors:  Qin Feng; Hengbin Wang; Huck Hui Ng; Hediye Erdjument-Bromage; Paul Tempst; Kevin Struhl; Yi Zhang
Journal:  Curr Biol       Date:  2002-06-25       Impact factor: 10.834

8.  Pyrazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1).

Authors:  Ashok V Purandare; Zhong Chen; Tram Huynh; Suhong Pang; Jieping Geng; Wayne Vaccaro; Michael A Poss; Jonathan Oconnell; Kimberly Nowak; Lata Jayaraman
Journal:  Bioorg Med Chem Lett       Date:  2008-06-12       Impact factor: 2.823

9.  N-Benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1).

Authors:  Martin Allan; Sukhdev Manku; Eric Therrien; Natalie Nguyen; Sylvia Styhler; Marie-France Robert; Anne-Christine Goulet; Andrea J Petschner; Gabi Rahil; A Robert Macleod; Robert Déziel; Jeffrey M Besterman; Hannah Nguyen; Amal Wahhab
Journal:  Bioorg Med Chem Lett       Date:  2008-12-24       Impact factor: 2.823

10.  Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group.

Authors:  Joanne M Hilden; Patricia A Dinndorf; Sharon O Meerbaum; Harland Sather; Doojduen Villaluna; Nyla A Heerema; Ron McGlennen; Franklin O Smith; William G Woods; Wanda L Salzer; Helen S Johnstone; Zoann Dreyer; Gregory H Reaman
Journal:  Blood       Date:  2006-03-23       Impact factor: 22.113

View more
  38 in total

1.  MLL leukemia induction by genome editing of human CD34+ hematopoietic cells.

Authors:  Corina Buechele; Erin H Breese; Dominik Schneidawind; Chiou-Hong Lin; Johan Jeong; Jesus Duque-Afonso; Stephen H K Wong; Kevin S Smith; Robert S Negrin; Matthew Porteus; Michael L Cleary
Journal:  Blood       Date:  2015-08-26       Impact factor: 22.113

Review 2.  Chromatin proteins and modifications as drug targets.

Authors:  Kristian Helin; Dashyant Dhanak
Journal:  Nature       Date:  2013-10-24       Impact factor: 49.962

3.  Bromo-deaza-SAH: a potent and selective DOT1L inhibitor.

Authors:  Wenyu Yu; David Smil; Fengling Li; Wolfram Tempel; Oleg Fedorov; Kong T Nguyen; Yuri Bolshan; Rima Al-Awar; Stefan Knapp; Cheryl H Arrowsmith; Masoud Vedadi; Peter J Brown; Matthieu Schapira
Journal:  Bioorg Med Chem       Date:  2013-01-30       Impact factor: 3.641

Review 4.  Inhibitors of Protein Methyltransferases and Demethylases.

Authors:  H Ümit Kaniskan; Michael L Martini; Jian Jin
Journal:  Chem Rev       Date:  2017-03-24       Impact factor: 60.622

5.  Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.

Authors:  Henrik Möbitz; Rainer Machauer; Philipp Holzer; Andrea Vaupel; Frédéric Stauffer; Christian Ragot; Giorgio Caravatti; Clemens Scheufler; Cesar Fernandez; Ulrich Hommel; Ralph Tiedt; Kim S Beyer; Chao Chen; Hugh Zhu; Christoph Gaul
Journal:  ACS Med Chem Lett       Date:  2017-02-14       Impact factor: 4.345

6.  Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

Authors:  Scott R Daigle; Edward J Olhava; Carly A Therkelsen; Aravind Basavapathruni; Lei Jin; P Ann Boriack-Sjodin; Christina J Allain; Christine R Klaus; Alejandra Raimondi; Margaret Porter Scott; Nigel J Waters; Richard Chesworth; Mikel P Moyer; Robert A Copeland; Victoria M Richon; Roy M Pollock
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

Review 7.  Histone lysine methyltransferases as anti-cancer targets for drug discovery.

Authors:  Qing Liu; Ming-Wei Wang
Journal:  Acta Pharmacol Sin       Date:  2016-07-11       Impact factor: 6.150

8.  Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.

Authors:  Chao Chen; Hugh Zhu; Frédéric Stauffer; Giorgio Caravatti; Susanne Vollmer; Rainer Machauer; Philipp Holzer; Henrik Möbitz; Clemens Scheufler; Martin Klumpp; Ralph Tiedt; Kim S Beyer; Keith Calkins; Daniel Guthy; Michael Kiffe; Jeff Zhang; Christoph Gaul
Journal:  ACS Med Chem Lett       Date:  2016-06-01       Impact factor: 4.345

9.  Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket.

Authors:  Clemens Scheufler; Henrik Möbitz; Christoph Gaul; Christian Ragot; Céline Be; César Fernández; Kim S Beyer; Ralph Tiedt; Frédéric Stauffer
Journal:  ACS Med Chem Lett       Date:  2016-06-06       Impact factor: 4.345

10.  3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1.

Authors:  Fangrui Wu; Chao Zhou; Yuan Yao; Liping Wei; Zizhen Feng; Lisheng Deng; Yongcheng Song
Journal:  J Med Chem       Date:  2015-12-24       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.